NuCana plc (NCNA) ADR Each Representing 0.04 Ord Shares SPON
Sell:$1.05Buy:$1.07
$0.03
(2.83%)
- This stock can be held in a
Stocks and Shares ISA
SIPP$0.03
(2.83%)$0.03
(2.83%)Company Information
About this company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Key people
Key facts
- EPIC-
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS67022C2052
- Market cap$3.79m
- Employees25
- Shares in issue0.00
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.